BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25297758)

  • 21. Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.
    Ghielmini M
    Cancer Treat Rev; 2005 Dec; 31(8):644-7. PubMed ID: 16289339
    [No Abstract]   [Full Text] [Related]  

  • 22. A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy.
    Kamata M; Sugaya M; Miyagaki T; Sonoda K; Ichimura Y; Mitsui H; Sato S; Kamikubo Y; Kurokawa M
    Int J Dermatol; 2014 Jan; 53(1):e24-6. PubMed ID: 23452101
    [No Abstract]   [Full Text] [Related]  

  • 23. Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites.
    Hiroshima Y; Tajima K; Shiono Y; Suzuki I; Kouno K; Yamamoto M; Kato Y; Kato T
    Ann Hematol; 2012 Sep; 91(9):1499-500. PubMed ID: 22281990
    [No Abstract]   [Full Text] [Related]  

  • 24. [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
    Palacios Abufón A; Acebo Mariñas E; Gardeazabal García J; García-Ruiz JC
    Actas Dermosifiliogr; 2012 Apr; 103(3):253-5. PubMed ID: 22093542
    [No Abstract]   [Full Text] [Related]  

  • 25. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel treatment strategies in follicular lymphoma.
    Buske C; Dreyling H; Unterhalt M; Hiddemann W
    Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
    Hernandez MC; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thyroid malignant lymphoma].
    Noh JY; Shimizu T; Ito K
    Nihon Rinsho; 2006 May; Suppl 1():482-4. PubMed ID: 16776195
    [No Abstract]   [Full Text] [Related]  

  • 29. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary gastrointestinal follicular lymphoma with histological transformation.
    Hangai S; Nakamura F; Kamikubo Y; Ichikawa M; Suzuki H; Yoshida S; Yamada A; Takazawa Y; Fukayama M; Koike K; Kurokawa M
    Ann Hematol; 2013 Jul; 92(7):993-4. PubMed ID: 23271213
    [No Abstract]   [Full Text] [Related]  

  • 32. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary effusion lymphoma (PEL) revisited: a hematologist's perspective.
    Desai S; Freeman NJ
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):60-1. PubMed ID: 16163162
    [No Abstract]   [Full Text] [Related]  

  • 35. Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma.
    McClanahan F; Hielscher T; Rieger M; Hensel M; Bentz M; Schmidt-Wolf I; Käbisch A; Salwender H; Dürk H; Staiger H; Mandel T; Neben K; Hillengass J; Leo E; Krämer A; Ho AD; Witzens-Harig M
    Am J Hematol; 2012 Oct; 87(10):E68-71. PubMed ID: 22847344
    [No Abstract]   [Full Text] [Related]  

  • 36. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Fabbri A; Gozzetti A; Rigacci L
    Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
    [No Abstract]   [Full Text] [Related]  

  • 37. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.
    Bermúdez A; Marco F; Conde E; Mazo E; Recio M; Zubizarreta A
    Haematologica; 2000 Aug; 85(8):894-5. PubMed ID: 10942955
    [No Abstract]   [Full Text] [Related]  

  • 38. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
    Johnston A; Salles G; Espinouse D; Felman P; André P; Berger F; Coiffier B
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A rare thyroid tumor].
    Tabareau F; Ragage F; Berger F; Berger N; Guterman R; Bruch JF
    Ann Pathol; 2010 Apr; 30(2):148-50. PubMed ID: 20451076
    [No Abstract]   [Full Text] [Related]  

  • 40. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
    Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
    Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.